Pralsetinib is an anti-tumor drug targeting RET gene mutations, mainly used to treat RET fusion positive non-small cell lung cancer and thyroid cancer, providing precise treatment options for patients with specific gene mutations.

1. Non small cell lung cancer

(1) Indications: Treatment for adult patients with metastatic RET fusion positive non-small cell lung cancer, especially for cases of traditional treatment failure.

(2) Clinical value: Designated by the FDA as an orphan drug for the treatment of JAK1/2 positive or TRKC positive non-small cell lung cancer, filling the gap in targeted therapy.

2. Thyroid cancer

(1) Target audience: Late stage or metastatic RET fusion positive thyroid cancer patients aged 12 years and above, as well as children.

(2) Treatment characteristics: Especially suitable for refractory cases caused by radioactive iodine, and has been granted orphan drug status by the FDA.

3. Other solid tumors

(1) Extended application: It also shows therapeutic potential for other solid tumors carrying RET gene mutations, such as medullary thyroid carcinoma.

(2) Medication restriction: RET mutation status must be confirmed through genetic testing before use.